according to Sudfoite, BioNTech envisions a future where the immune system is trained to recognize and target “hyper-personalized” cancer cells using mRNA technology. Shahin expects the first mRNA-based cancer vaccine to be approved by 2030. A breakthrough could occur as BioNTech works to obtain research data on various therapeutic approaches between 2025 and 2029.
Positive results from these studies could pave the way for the approval of innovative cancer vaccines and usher in a new era in medicine. At the heart of Biontech’s approach is cancer immunotherapy, a way to harness the body’s natural defense system to fight cancer. Shahin emphasizes the importance of immunotherapies currently in clinical development for various cancers.
But the goal is not just control, but ideally a long-term cure for cancer. Biontech aims to create a technological framework that can quickly plan all the steps required for cancer treatment. This involves receiving a patient’s blood and tumor samples and administering a personalized cancer vaccine within four weeks.
